Close Menu

NEW YORK – NantHealth said Thursday after the close of the market that its first quarter revenues fell 10 percent year over year to $18.2 million from $20.2 million.

For the quarter ended March 31, NantHealth had total software-related revenues of $18.1 million, up 2 percent from $17.8 million in Q1 2019. All software-related revenues now come from software-as-a-service (SaaS) offerings.

Revenue from sequencing and molecular analysis slipped 93 percent to $59,000 from $814,000 a year earlier. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.